Patients with CKD are frequently treated with a multi-drug regimen, usually including antihyperglycemics, antihypertensive agents, most commonly renin–angiotensin–aldosterone system (RAAS) inhibitors, antihyperuricemics, diuretics, statins, and vitamin D analogs, Although polypharmacy is considered to be a risk factor for sarcopenia, there are only limited data concerning the contribution of these drugs to the development of sarcopenia in patients with CKD, especially in patients with NDD-CKD. The gene discussed is REN; the disease is sarcopenia.